Product nameAnti-HARS antibody [EPR9450(B)(ABC)]
See all HARS primary antibodies
DescriptionRabbit monoclonal [EPR9450(B)(ABC)] to HARS
Tested applicationsSuitable for: WB, IHC-P, IPmore details
Unsuitable for: Flow Cyt or ICC/IF
Species reactivityReacts with: Human
Synthetic peptide within Human HARS aa 1-100. The exact sequence is proprietary.
- Recombinant Human HARS protein (ab99387) can be used as a positive control in WB. HeLa, 293T and K562 cell lysates; Human kidney tissue.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.
This product is a recombinant rabbit monoclonal antibody.
Storage instructionsShipped at 4°C. Store at -20ºC.
Storage bufferPreservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol, 0.05% BSA, 50% Tissue culture supernatant
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab140640 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/10000. Predicted molecular weight: 57 kDa.|
|IHC-P||1/50 - 1/100. Perform heat mediated antigen retrieval before commencing with IHC staining protocol. Heat up to 98 oC, below boiling, and then let cool for 10-20 min|
|IP||1/10 - 1/100.|
Tissue specificityBrain, heart, liver and kidney.
Involvement in diseaseDefects in HARS are a cause of Usher syndrome type 3B (USH3B) [MIM:614504]. USH3B is a syndrome characterized by progressive vision and hearing loss during early childhood. Some patients have the so-called 'Charles Bonnet syndrome,' involving decreased visual acuity and vivid visual hallucinations. USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH3 is characterized by postlingual, progressive hearing loss, variable vestibular dysfunction, and onset of retinitis pigmentosa symptoms, including nyctalopia, constriction of the visual fields, and loss of central visual acuity, usually by the second decade of life.
Sequence similaritiesBelongs to the class-II aminoacyl-tRNA synthetase family.
Contains 1 WHEP-TRS domain.
- Information by UniProt
- cytoplasmic antibody
- EC 22.214.171.124 antibody
- FLJ20491 antibody
All lanes : Anti-HARS antibody [EPR9450(B)(ABC)] (ab140640) at 1/1000 dilution
Lane 1 : HeLa cell lysate
Lane 2 : 293T cell lysate
Lane 3 : K562 cell lysate
Lysates/proteins at 10 µg per lane.
All lanes : HRP-labelled Goat-anti-Rabbit at 1/2000 dilution
Predicted band size: 57 kDa
Immunohistochemical analysis of paraffin-embedded Human kidney tissue labelling HARS with ab140640 at 1/50 dilution.
ab140640 has not yet been referenced specifically in any publications.